Prediction of long‐term survival for clinical stage I malignant melanoma and guidance of therapy has long relied upon assessment of tumor thickness. This parameter is a strong, but not infallible predictor of prognosis. Clark et al. have developed a prognostic model based upon the concept of tumor progression and the evaluation of six readily assessable clinical and histologic attributes. They report the most accurate prediction of long‐term survival of any prognostic method available for melanoma (100% accurate for radial‐growth‐phase and 84.1% accurate for vertical‐growth‐phase melanomas). This model was developed and validated via study of a patient population which largely resided in the northeastern portion of the United States. We report additional validation of this model using a data base of 55 patients from a different geographic location (North Carolina) and have observed virtual identity in the accuracy of predicting 8‐year survival for radial‐growth‐phase (100%) and vertical‐growth‐phase (85.1%) melanomas. Twenty per cent of these cases were randomly selected and subjected to re‐evaluation for prognosis with extremely good precision obtained in th